首页 > 市场调查报告书 > 製药

药物开发以基因为基之药物开发

生物模拟市场规模、份额和成长分析（按产品、应用、治疗领域、实施模式、定价模式、最终用途和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1897596

生物模拟市场规模、份额和成长分析（按产品、应用、治疗领域、实施模式、定价模式、最终用途和地区划分）－2026-2033年产业预测

Biosimulation Market Size, Share, and Growth Analysis, By Product (Software, Services), By Application (Drug Development, Drug Discovery), By Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月16日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，生物模拟市场规模将达到 46.9 亿美元，到 2025 年将达到 55 亿美元，到 2033 年将达到 195.7 亿美元，在预测期（2026-2033 年）内，复合年增长率为 17.2%。

由于模拟软体的进步，生物仿真市场正在迅速扩张。这些软体透过数学框架对现实世界系统进行建模，能够改善系统的行为、特性和互动方式，从而带来显着效益，例如降低培训和製造成本、提高产品品质和提升生产效率。这反过来又有助于减少产品召回，而产品召回是製造商最关注的问题之一。关键成长要素包括医疗领域软体应用的不断开发，以及模拟工具在汽车、电子和航太等多个行业的日益普及。此外，近期全球健康危机加速了数位科技的应用，使得模拟软体对于优化业务流程和最大限度减少人际接触至关重要，凸显了其在解决医疗保健挑战方面的重要性。

生物模拟市场驱动因素

生物模拟市场的主要驱动力是各行业对高性价比解决方案日益增长的需求。随着企业寻求降低营运成本，模拟软体的应用正在蓬勃发展。这项技术能够实现虚拟测试和分析，使企业能够以更有效率、更经济的方式取代昂贵的实体原型和传统测试方法。透过生物仿真，企业可以简化开发流程、降低风险、加速创新并控製成本。这一趋势表明，人们越来越认识到先进模拟工具在提高生产力和优化资源利用方面具有重要价值，并已在多个领域中得到应用。

压制生物模拟市场

儘管生物模拟市场具有许多优势，但其主要阻碍因素在于实施模拟软体所需的高昂初始投资。这不仅包括许可费，还包括硬体升级和必要的人员培训费用。对于预算有限的中小型企业而言，这笔财务负担尤其沉重。因此，高昂的初始成本可能会阻碍生物模拟技术的应用，限制其在业界的广泛普及。由此可见，财务因素仍然是许多潜在用户进入该领域的重要障碍。

生物模拟市场趋势

将人工智慧 (AI) 技术应用于生物模拟领域，以提高其准确性和效率，已成为该领域的一大趋势。 AI 驱动的生物模拟工具能够提供预测性洞察，从而实现即时性能最佳化，彻底改变医疗保健和自动驾驶汽车等产业。这种转变不仅提升了生物模拟的价值，也使企业更有效地应对复杂多变的环境。对先进建模和模拟能力的需求持续成长，这使得 AI 成为推动生物模拟领域研发和系统效率提升的关键驱动力。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Simulations Plus, Inc.（USA）
Dassault Systemes（France）
Schrodinger, LLC（USA）
ACD/Labs（Canada）
Chemical Computing Group（Canada）
Physiomics PLC（UK）
Evidera（USA）
In Silico Biosciences, Inc.（USA）
INOSIM Software GmbH（Germany）
Insilico Biotechnology AG（Germany）
LeadInvent Technologies（India）
Rosa & Co. LLC（USA）
Genedata AG（Switzerland）

结论与建议

简介目录

Product Code: SQMIG35I2104

Biosimulation Market size was valued at USD 4.69 Billion in 2024 and is poised to grow from USD 5.5 Billion in 2025 to USD 19.57 Billion by 2033, growing at a CAGR of 17.2% during the forecast period (2026-2033).

The biosimulation market is rapidly expanding due to advancements in simulation software that models real-world systems through mathematical frameworks. These tools enhance system behaviors, properties, and interactions, delivering significant advantages such as lower training and manufacturing costs, improved product quality, and enhanced productivity. As a result, they help mitigate product recalls, a major concern for manufacturers. Key growth drivers include the rising development of software applications in medicine and the increasing implementation of simulation tools across multiple sectors like automotive, electronics, and aerospace. Additionally, the recent global health crisis has accelerated the adoption of digital technologies, making simulation software essential for optimizing processes and minimizing physical interactions in operations, highlighting its vital role in addressing healthcare challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biosimulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biosimulation Market Segments Analysis

Global Biosimulation Market is segmented by Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use and region. Based on Product, the market is segmented into Software and Services. Based on Application, the market is segmented into Drug Development, Drug Discovery and Others. Based on Therapeutic Area, the market is segmented into Oncology, Neurology, Cardiology and Others. Based on Deployment Model, the market is segmented into On-premise and Cloud-based. Based on Pricing Model, the market is segmented into Subscription and Ownership. Based on End Use, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes and Regulatory Authorities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biosimulation Market

The biosimulation market is primarily propelled by the growing demand for cost-effective solutions across various industries. As organizations look to lower their operational expenses, the adoption of simulation software has surged. This technology facilitates virtual testing and analysis, allowing businesses to substitute expensive physical prototypes and traditional testing methods with more efficient and economical alternatives. By leveraging biosimulation, companies can streamline their development processes, mitigate risks, and accelerate innovation, all while keeping costs in check. This trend underscores the increasing recognition of the value that advanced simulation tools bring to enhancing productivity and optimizing resource utilization in diverse sectors.

Restraints in the Biosimulation Market

Although the biosimulation market offers numerous benefits, a major constraint lies in the substantial initial investment required for simulation software. This includes not only the costs of licensing but also expenses related to hardware upgrades and necessary staff training. Such financial burdens can be particularly challenging for small and medium-sized enterprises (SMEs), which often operate within tight budgets. As a result, these high upfront costs may deter some businesses from adopting biosimulation technologies, limiting wider accessibility and utilization within the industry. Thus, financial considerations remain a crucial barrier to entry for many potential users.

Market Trends of the Biosimulation Market

The biosimulation market is witnessing a significant trend driven by the integration of Artificial Intelligence (AI) technologies, enhancing the accuracy and efficiency of simulations. AI-powered biosimulation tools are revolutionizing industries like healthcare and autonomous vehicles by delivering predictive insights that facilitate real-time performance optimization. This shift not only elevates the value of biosimulations but also empowers organizations to navigate complex and dynamic environments more effectively. The demand for advanced modeling and simulation capabilities continues to rise, positioning AI as a key enabler in advancing research, drug development, and system efficiencies within the biosimulation landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Patent Analysis

Global Biosimulation Market Size by Product & CAGR (2026-2033)

Market Overview
Software
Services

Global Biosimulation Market Size by Application & CAGR (2026-2033)

Market Overview
Drug Development
Drug Discovery
Others

Global Biosimulation Market Size by Therapeutic Area & CAGR (2026-2033)

Market Overview
Oncology
Neurology
Cardiology
Others

Global Biosimulation Market Size by Deployment Model & CAGR (2026-2033)

Market Overview
On-premise
Cloud-based

Global Biosimulation Market Size by Pricing Model & CAGR (2026-2033)

Market Overview
Subscription
Ownership

Global Biosimulation Market Size by End Use & CAGR (2026-2033)

Market Overview
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Regulatory Authorities

Global Biosimulation Market Size & CAGR (2026-2033)

North America (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- US
- Canada
Europe (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Simulations Plus, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dassault Systemes (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Schrodinger, LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ACD/Labs (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chemical Computing Group (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Physiomics PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evidera (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In Silico Biosciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
INOSIM Software GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insilico Biotechnology AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LeadInvent Technologies (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rosa & Co. LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genedata AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments